1. Germany Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Dermapharm Holding SE

Dermapharm Holding SE

38.50
EUR
-0.30
(-0.77%)
2.76EPS
17.04P/E
2.35BMarket Cap
Nov 12Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
7.27
7.15
8.9
9.35
10.72
13.02
14.74
17.51
19.03
21.09
21.93
21.64
22.41
Basic EPS, GAAP
- -
- -
0.24
1.54
1.56
1.41
1.43
1.59
3.89
2.49
1.16
2.11
2.46
2.78
Free Cash Flow per Basic Share
- -
0.48
0.47
1.18
0.15
2.49
1.01
1.68
3.51
4.63
3.3
3.03
3.47
4.1
Dividend per Share
- -
0.1
- -
- -
- -
- -
0.77
0.8
0.88
2.17
1.05
0.88
0.9
- -
Book Value per Share
0.66
0.53
0.76
1.06
1.37
4.69
5.18
5.98
9.24
9.87
10.01
11.23
12.9
10.83
Tangible Book Value per Share
-1.14
-1.21
-0.8
-0.56
-1.57
0.15
-4.02
-4.49
-1.16
-0.83
-10.85
-8.99
-6.93
-10.95
Basic Weighted Avg Shares
54
54
54
50
50
53
54
54
54
54
54
54
54
53
Sales/Revenue/Turnover
- -
391
385
444
467
572
701
794
943
1,025
1,135
1,181
1,165
1,181
Operating Margin (%)
- -
11.3
17.58
19.33
19.44
18.87
17.08
18.3
30.44
23.62
15.86
18.19
19.51
22.41
Depreciation Expense
- -
18
15
14
16
30
48
47
55
95
102
87
92
125
Net Income, GAAP
- -
- -
13
77
78
75
77
86
210
134
62
114
132
147
Effective Tax Rate (%)
- -
6.32
5.28
7.09
11.68
27.83
29.3
31.41
28.7
38.69
42.89
35.04
28.42
24.5
Profit Margin (%)
- -
-0.02
3.3
17.32
16.64
13.16
11.01
10.81
22.23
13.1
5.49
9.64
11.37
12.4
Working Capital
13
72
81
42
112
225
251
267
364
316
236
267
360
318
LT Debt
101
162
151
97
222
233
543
581
575
512
964
890
923
1,030
Total Equity
41
34
44
61
74
256
284
325
500
532
545
608
691
533
Return on Invested Capital (%)
- -
19.45
25.86
35.43
28.78
16.84
11.74
10.45
20.41
13
7.22
8.32
9.22
11.53
Return on Capital (%)
- -
4.58
10.55
38.59
30.47
17.95
11.96
10.41
21.53
13.47
7.15
9.57
10.11
11.06
Return on Common Equity (%)
- -
-0.19
36.61
157.1
119.06
46.19
29.07
28.58
51.16
26.09
11.65
19.9
20.39
25.6

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
129
- -
139
LT Borrowings
904
- -
1,013
LT Finance Leases
19
- -
17
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
54
54
50
Market Capitalization
2,097
2,256
2,346

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
703
780
764
Cash, Cash Equivalents & STI
204
254
224
Accounts Receivable, Net
110
136
137
Inventories
325
360
371
Total Current Liabilities
343
390
446
Payables & Accruals
- -
- -
- -
ST Debt
129
- -
139
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
41.88%
17.61%
13.56%
Free Cash Flow
184.3%
23.81%
14.64%
Net Income, GAAP
67.13%
30.7%
16.37%
Sales/Revenue/Turnover
11.97%
8.18%
-1.34%
Total Cash Common Dividend
- -
18.21%
2.27%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
299
280
312
291
1,181
2025
302
272
295
296
1,165
2026
306
285
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.81
0.32
0.6
0.38
2.11
2025
0.62
0.39
0.77
0.69
2.46
2026
0.84
0.47
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.88
2025
- -
- -
- -
- -
0.9
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hans-Georg Feldmeier
Full Time Employees
3,500
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Lil-Dagover-Ring 7 Grunwald BV Germany 82031
IPO Date
Feb 9, 2018
Website
ir.dermapharm.de
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Dermapharm Holding SE manufactures and distributes branded pharmaceuticals, other healthcare products, and parallel imports primarily in Europe with an expanding international footprint. Founded in 1991 and headquartered in Grünwald near Munich, Germany, the company operates an integrated business model encompassing in-house research and development, production at sites including its main facility in Brehna near Leipzig, quality management, logistics, and sales through a dedicated pharmaceutical sales force; Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG. The branded pharmaceuticals segment features over 1,300 marketing authorizations with more than 390 active pharmaceutical ingredients focused on niche therapeutic areas such as dermatology (e.g., Ampho-Moronal, Volon), vitamins/minerals/food supplements, allergology (e.g., Allergovit, Acaroid, Novo-Helisen via Allergopharma), pain and inflammation, cardiovascular support, gynecology, and urology, where it holds leading market positions in Germany; the other healthcare products segment includes food supplements, herbal pharmaceuticals, cosmetics, medical devices (e.g., bite away, Herpotherm), herbal extracts via Euromed S.A., pollen extracts via AB Cernelle, and medicinal cannabis via Candoro ethics; the parallel import business under axicorp imports originator pharmaceuticals from EU states for resale in Germany, ranking seventh by revenue. Operations span Germany, Austria, Switzerland, Croatia, Poland, Ukraine, Italy, Spain, France (via Arkopharma), Sweden (via Cernelle), and the United States, with exports to over 50 countries and approximately 3,455 employees worldwide. Recent developments include ongoing restructuring at subsidiaries such as axicorp, mibe Vertrieb, Euromed, and Arkopharma to optimize contribution margins, portfolio adjustments in parallel imports by delisting low-margin products, confirmed 2025 guidance for revenue of EUR 1,160-1,200 million and adjusted EBITDA of EUR 322-332 million amid stable earnings and strong branded pharmaceuticals growth, investments in intangible assets at mibe, Arkopharma, and Cernelle, and sustained organic expansion in high-margin core portfolio and international markets including new medically relevant extracts launch in 2025.